# A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

> **NCT07255664** · PHASE1,PHASE2 · RECRUITING · sponsor: **Curacell Holding AB** · enrollment: 12 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer
- Prostate Cancer Metastatic
- Prostate Cancer Locally Advanced

## Interventions

- **DRUG:** CC-38
- **DRUG:** Pembrolizumab
- **DRUG:** Cyclophosphamid
- **DRUG:** Interleukin-2
- **DRUG:** Uromitexan

## Key facts

- **NCT ID:** NCT07255664
- **Lead sponsor:** Curacell Holding AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-13
- **Primary completion:** 2027-04
- **Final completion:** 2029-04
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07255664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07255664, "A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07255664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*